Dermatology CRO Market Size, Share | Research Report [2033]
The global dermatology CRO market size was exhibited at USD 4,738.80 million in 2023 and is projected to hit around USD 9,235.18 million by 2033, growing at a CAGR of 6.9% during the forecast period of 2024 to 2033.
.jpg "Dermatology CRO Market Size 2024 To 2033")
Key Takeaways:
Dermatology CRO Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 4,738.80 Million |
| Market Size by 2033 | USD 9,235.18 Million |
| Growth Rate From 2024 to 2033 | CAGR of 6.9% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type, Service Type, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | IQVIA Inc.; Labcorp Drug Development; Pharmaceutical Product Development, LLC (PPD) (Thermo Fisher Scientific Inc.); Parexel International Corp.; Charles River Laboratories; Icon, Plc; Medidata; Syneos Health; Pharmaron; ragen Life Sciences Ltd.; Wuxi AppTec; MEDPACE; CTI Clinical Trial & Consulting; Bioskin; Proinnovera GmbH; Biorasi, LLC; Javara; TFS. |
The high burden of various dermatological conditions, such as alopecia areata, atopic dermatitis, and acne, contributing to the demand for research, is one of the major factors driving market growth. Furthermore, dermatological contract research organizations (CROs) are gaining traction owing to the growing interest of dermatological companies in focusing on their core competencies, such as marketing and sales, which is further contributing to market growth. A significant number of people worldwide suffer from various skin conditions.
For instance, in 2023, the Asthma and Allergy Foundation of America stated that around 16.5 million people in America suffer from atopic dermatitis. Similarly, according to the WHO, over 1.2 million people worldwide had non-melanoma skin cancer in 2020. The high burden of skin disorders across the globe is anticipated to improve the demand for dermatological clinical trials, thus creating growth opportunities for the market. The public organization is actively providing funding to conduct dermatological research efficiently. For instance, in 2023, The National Psoriasis Foundation Funds announced USD 3.2 million as funding in the research awards. Such funding by the public organization is expected to promote the number of CRO activities in the foreseeable future.
The outbreak of the COVID-19 pandemic had a damaging effect on the overall pharmaceutical industry. Supply chain disruption and delays in conducting clinical research in the area of dermatology have slowed market growth. However, the COVID-19 pandemic has highlighted the importance of virtual trials and the use of technology and software solutions. In the future, the dermatology CRO environment is expected to be transformed by the increasing usage of machine learning (ML)-based platforms, artificial intelligence (AI), and innovative trial designs. This is expected to support the market in the forecasted period.
Type Insights
The clinical-type segment dominated the market in 2023 with a revenue share of over 77.0%. The high cost associated with clinical research is a major factor for the largest segment share. Clinical trials are more expensive as compared to preclinical and drug discovery studies. The high cost associated with clinical studies is creating demand for outsourcing dermatological clinical trials. People living in developed and developing economies have a high disposable income, due to which there is a high adoption of new dermatological treatments among them. This supports the demand for new treatment options and, hence, the demand for clinical studies in dermatology, thus promoting segment growth. In the case of rare dermatological disorders, it is difficult to find a potential treatment for a small population; in such cases, outsourcing such trials will be more convenient for the company to reduce the cost and time incurred in conducting trials and enrolling such patients for studies.
All the aforementioned factors support the growth of the clinical segment. The preclinical segment is expected to register the highest CAGR of 6.7% over the forecast period. The rising number of preclinical trials involving large molecules and the growing need to reduce R&D costs are likely to drive the demand for dermatology CRO services, resulting in market expansion. A significant number of pharmaceutical companies lack suitable laboratories for conducting preclinical trials; thus, outsourcing these studies could be helpful for them to reduce the cost and time associated with conducting research; also, outsourcing will help them obtain quality preclinical study results. These factors are expected to further support the growth of the preclinical-type segment.
Service Type Insights
The clinical monitoring segment accounted for the largest revenue share of more than 20% in 2023 and is expected to maintain its position during the forecast period. This could be due to an increase in the number of clinical trials and the need to monitor those trials, which is driving up demand for services. Over the last decade, dermatology clinical research has been outsourced to CROs for a variety of reasons, including cost-effectiveness and technical knowledge. The use of smart analytics and real-time data capture technologies in the healthcare sector is expected to improve clinical monitoring data. Real-time data collection on medication safety and toxicity allows for early detection of trial flaws and prompt corrections, such as trial re-design or termination, propelling segment growth.
The regulatory/medical affairs segment is expected to grow at the fastest CAGR of 8.8% during the forecast period. The globalization of clinical trials, differences in drug regulations globally, increasing demand to obtain approval for new products, and maintaining compliance are the major factors boosting segment growth. Apart from this, the significant number of investments in clinical research for skin cancer, dermatitis, and psoriasis promoting the demand for product registration and clinical trial applications are other factors supporting segment growth.
Regional Insight
In 2023, Asia Pacific dominated the market with a revenue share of over 44.0% and is expected to grow rapidly in the forecast period. This is due to the diversity in population, the high prevalence of chronic illnesses, such as eczema, melasma, psoriasis, and melanoma, in the region, and the ease with which patients may be recruited and retained. Furthermore, the cost of conducting clinical research in the region is comparatively less as compared to developed countries, and the region also has advanced infrastructure for conducting dermatological studies. All the above-mentioned factors are boosting market growth in the region. The North American region is expected to grow at a CAGR of 5.2% during the forecast period.
The growth of this regional market has also been fueled by the increasing support of public organizations for R&D activities through investments and grants to research institutes and corporations. For instance, as of 2023, the National Psoriasis Foundation in the U.S. has provided over $30 million in funding for conducting research for the treatment, prevention, and cure of psoriasis. Such funding is likely to support market growth. Apart from this, the region also spends a significant amount on aesthetic surgeries. For instance, the Aesthetic Society stated in 2021 that Americans spent over USD 8.7 billion on aesthetic plastic surgeries. The high spending to make it look more appealing is expected to improve researchers' interest in developing new treatments. This is further supporting regional market growth.
Some of the prominent players in the dermatology CRO market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global dermatology CRO market.
Type
Service
By Region
Chapter 1. Research Methodology And Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Type
1.1.3. Service Type
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Dermatology CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing adoption of advanced technologies
3.2.1.2. Growing interest to look more appealing
3.2.1.3. Increasing outsourcing of R&D activities
3.2.1.4. Favorable environment for clinical trials in developing countries
3.2.2. Market Restraint Analysis
3.2.2.1. Quality issues of CRO services
3.2.2.2. Intellectual property rights issues
3.3. Dermatology CRO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Dermatology CRO Market: Type Estimates & Trend Analysis
4.1. Dermatology CRO Market, By Type: Segment Dashboard
4.2. Dermatology CRO Market, By Type: Movement Analysis
4.3. Dermatology CRO Market Estimates & Forecasts, By Type, 2021 - 2033
4.3.1. Drug Discovery
4.3.1.1. Drug Discovery Market, 2021 to 2033
4.3.1.2. Target Validation
4.3.1.2.1. Target Validation Market, 2021 to 2033
4.3.1.3. Lead Identification
4.3.1.3.1. Lead Identification Market, 2021 to 2033
4.3.1.4. Lead Optimization
4.3.1.4.1. Lead Optimization Market, 2021 to 2033
4.3.2. Preclinical
4.3.2.1. Preclinical Market, 2021 to 2033
4.3.3. Clinical
4.3.3.1. Clinical Market, 2021 to 2033
4.3.3.2. Phase I
4.3.3.2.1. Phase I Market, 2021 to 2033
4.3.3.3. Phase II
4.3.3.3.1. Phase II Market, 2021 to 2033
4.3.3.4. Phase III
4.3.3.4.1. Phase III Market, 2021 to 2033
4.3.3.5. Phase IV
4.3.3.5.1. Phase IV Market, 2021 to 2033
Chapter 5. Dermatology CRO Market: Service Type Estimates & Trend Analysis
5.1. Dermatology CRO Market, By Service Type: Segment Dashboard
5.2. Dermatology CRO Market, By Service Type: Movement Analysis
5.3. Dermatology CRO Market Estimates & Forecasts, By Service Type, 2021 - 2033
5.3.1. Project Management/Clinical Supply Management
5.3.1.1. Project Management/Clinical Supply Management Market, 2021 to 2033
5.3.2. Data Management
5.3.2.1. Data Management Market, 2021 to 2033
5.3.3. Regulatory/Medical Affairs
5.3.3.1. Regulatory/Medical Affairs Market, 2021 to 2033
5.3.4. Medical Writing
5.3.4.1. Medical Writing Market, 2021 to 2033
5.3.5. Clinical Monitoring
5.3.5.1. Clinical Monitoring Market, 2021 to 2033
5.3.6. Quality Management/ Assurance
5.3.6.1. Quality Management/ Assurance Market, 2021 to 2033
5.3.7. Bio-statistics
5.3.7.1. Bio-statistics Market, 2021 to 2033
5.3.8. Investigator Payments
5.3.8.1. Investigator Payments Market, 2021 to 2033
5.3.9. Laboratory
5.3.9.1. Laboratory Market, 2021 to 2033
5.3.10. Patient and site Recruitment
5.3.10.1. Patient and site Recruitment Market, 2021 to 2033
5.3.11. Laboratory
5.3.11.1. Laboratory Market, 2021 to 2033
5.3.12. Technology
5.3.12.1. Technology Market, 2021 to 2033
5.3.13. Others
5.3.13.1. Others Market, 2021 to 2033
Chapter 6. Dermatology CRO Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. North America
6.4.1. Market Estimates and Forecast, 2021 - 2033 (Revenue, USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework
6.5.1.4. UK Market Estimates and Forecasts, 2021 - 2033
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Germany Market Estimates and Forecasts, 2021 - 2033
6.5.3. France
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. France Market Estimates and Forecasts, 2021 - 2033
6.5.4. Italy
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Italy Market Estimates and Forecasts, 2021 - 2033
6.5.5. Spain
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Spain Market Estimates and Forecasts, 2021 - 2033
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Denmark Market Estimates and Forecasts, 2021 - 2033
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2021 - 2033
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Norway Market Estimates and Forecasts, 2021 - 2033
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework
6.6.1.4. Japan Market Estimates and Forecasts, 2021 - 2033
6.6.2. India
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. India Market Estimates and Forecasts, 2021 - 2033
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. China Market Estimates and Forecasts, 2021 - 2033
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. South Korea Market Estimates and Forecasts, 2021 - 2033
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033
6.6.6. Thailand
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework
6.6.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework
6.7.1.4. Brazil Market Estimates and Forecasts, 2021 - 2033
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Mexico Market Estimates and Forecasts, 2021 - 2033
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033
6.7.4. Colombia
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. Colombia Market Estimates and Forecasts, 2021 - 2033
6.7.5. Chile
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Chile Market Estimates and Forecasts, 2021 - 2033
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework
6.8.1.4. South Africa Market Estimates and Forecasts, 2021 - 2033
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework
6.8.3.4. UAE Market Estimates and Forecasts, 2021 - 2033
6.8.4. Israel
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework
6.8.4.4. Israel Market Estimates and Forecasts, 2021 - 2033
6.8.5. Iran
6.8.5.1. Key Country Dynamics
6.8.5.2. Competitive Scenario
6.8.5.3. Regulatory Framework
6.8.5.4. Iran Market Estimates and Forecasts, 2021 - 2033
6.8.6. Kuwait
6.8.6.1. Key Country Dynamics
6.8.6.2. Competitive Scenario
6.8.6.3. Regulatory Framework
6.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.1.1. Innovators
7.1.2. Market Leaders
7.1.3. Emerging Players
7.1.4. Company Market Share Analysis, 2022
7.2. Company Profiles
7.2.1. IQVIA, Inc.
7.2.1.1. Company Overview
7.2.1.2. Financial Performance
7.2.1.3. Service Benchmarking
7.2.1.4. Strategic Initiatives
7.2.2. Labcorp Drug Development
7.2.2.1. Company Overview
7.2.2.2. Financial Performance
7.2.2.3. Service Benchmarking
7.2.2.4. Strategic Initiatives
7.2.3. Aragen Life Sciences Ltd
7.2.3.1. Company Overview
7.2.3.2. Financial Performance
7.2.3.3. Service Benchmarking
7.2.3.4. Strategic Initiatives
7.2.4. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific Inc.)
7.2.4.1. Company Overview
7.2.4.2. Financial Performance
7.2.4.3. Service Benchmarking
7.2.4.4. Strategic Initiatives
7.2.5. Parexel International Corporation
7.2.5.1. Company Overview
7.2.5.2. Financial Performance
7.2.5.3. Service Benchmarking
7.2.5.4. Strategic Initiatives
7.2.6. Charles River Laboratories
7.2.6.1. Company Overview
7.2.6.2. Financial Performance
7.2.6.3. Service Benchmarking
7.2.6.4. Strategic Initiatives
7.2.7. Icon, Plc
7.2.7.1. Company Overview
7.2.7.2. Financial Performance
7.2.7.3. Service Benchmarking
7.2.7.4. Strategic Initiatives
7.2.8. Medidata
7.2.8.1. Company Overview
7.2.8.2. Financial Performance
7.2.8.3. Service Benchmarking
7.2.8.4. Strategic Initiatives.
7.2.9. Syneos Health
7.2.9.1. Company Overview
7.2.9.2. Financial Performance
7.2.9.3. Service Benchmarking
7.2.9.4. Strategic Initiatives
7.2.10. S Pharmaron
7.2.10.1. Company Overview
7.2.10.2. Financial Performance
7.2.10.3. Service Benchmarking
7.2.10.4. Strategic Initiatives
7.2.11. Wuxi Apptec
7.2.11.1. Company Overview
7.2.11.2. Financial Performance
7.2.11.3. Service Benchmarking
7.2.11.4. Strategic Initiatives
7.2.12. Medpace
7.2.12.1. Company Overview
7.2.12.2. Financial Performance
7.2.12.3. Service Benchmarking
7.2.12.4. Strategic Initiatives
7.2.12.5. CTI Clinical Trial & Consulting
7.2.13. CTI Clinical Trial & Consulting
7.2.13.1. Company Overview
7.2.13.2. Financial Performance
7.2.13.3. Service Benchmarking
7.2.13.4. Strategic Initiatives
7.2.14. Bioskin
7.2.14.1. Company Overview
7.2.14.2. Financial Performance
7.2.14.3. Service Benchmarking
7.2.14.4. Strategic Initiatives
7.2.15. Proinnovera GmbH
7.2.15.1. Company Overview
7.2.15.2. Financial Performance
7.2.15.3. Service Benchmarking
7.2.15.4. Strategic Initiatives
7.2.16. Biorasi, LLC
7.2.16.1. Company Overview
7.2.16.2. Financial Performance
7.2.16.3. Service Benchmarking
7.2.16.4. Strategic Initiatives
7.2.17. Javara
7.2.17.1. Company Overview
7.2.17.2. Financial Performance
7.2.17.3. Service Benchmarking
7.2.17.4. Strategic Initiatives
7.2.18. TFS
7.2.18.1. Company Overview
7.2.18.2. Financial Performance
7.2.18.3. Service Benchmarking
7.2.18.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers